ORMP News and Press, Oramed Pharmaceuticals Inc. From 01/11/23

Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes PR Newswire NEW YORK , Jan. 11, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the dev...

Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...

Oramed Pharma ( NASDAQ: ORMP ) said the United States Patent and Trademark Office had granted a patent to the company titled "Methods and Compositions for Treating Diabetes." ( ORMP ) is up 3.5% . The patent is an extension to a patent previously granted in May an...

Summary Oramed achieved positive results from phase 2 study using ORMD-0801 for Type 2 Diabetes patients with NASH. Primary safety endpoint and secondary exploratory biomarker endpoints established proof of concept. Results from the phase 3 study using ORMD-0801 for the treatment of pat...

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH PR Newswire Achieved primary endpoint of safety and tolerability in participants with Type 2 diabetes with NASH. Oral insulin candidate demonstrates ...

Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea PR Newswire Medicox to Distribute Oramed's Oral Insulin in South Korea , if approved Oramed to Receive Up to $18 Million in Developmental Milestones Oramed ...

Oramed Pharmaceuticals press release ( NASDAQ: ORMP ): Q3 GAAP EPS of -$0.18. Revenue of $2.02M (flat Y/Y). As of September 30, 2022, we had approximately $160 million in cash and investments, comprised of $33,196,000 of available cash, $121,119,000 of short-term bank ...

Oramed Reports Third Quarter 2022 Financial Results PR Newswire NEW YORK , Nov. 10, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company fo...

Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH PR Newswire Webinar scheduled for Thursday, November 17, 2022 , at 11:00 a.m. EST Featuring key opinion leader discussion on...

Oramed Pharmaceuticals ( NASDAQ: ORMP ) said oral COVID-19 vaccine candidate met the main and secondary goals of safety and immunogenicity as per preliminary data from a phase 1 trial. Oramed's unit Oravax Medical's oral vaccine candidate combines Oramed POD te...